November 7, 2023 07:14 AM ESTUpdated 08:22 AM
R&D

Ven­tyx Bio­sciences' stock drops over 70% af­ter ax­ing pso­ri­a­sis drug pro­gram

Katherine Lewin

News Reporter

Ven­tyx Bio­sciences has axed the de­vel­op­ment of its ex­per­i­men­tal pso­ri­a­sis drug af­ter lack­lus­ter Phase II re­sults, send­ing its stock plum­met­ing about 73% to $3.75 in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times